GlassScriptPhysician profile
Jean Mb Ly
NPI 1568623551
$13,604.43
in general payments reported to CMS, 2019-2025
38 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,051 · 2021: $1,317 · 2022: $2,722 · 2023: $2,321 · 2024: $2,370 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,387 · Consulting Fee: $16.52 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,386.80 |
| Consulting Fee | $16.52 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,487.82 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,367.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,275.52 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $1,115.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,098.36 | 2020-2025 | Takhzyro, Cinryze, Eohilia |
| Octapharma USA, INC. | $1,035.91 | 2019-2025 | Panzyga, Cutaquig |
| Regeneron Healthcare Solutions, INC. | $924.40 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $610.56 | 2019-2025 | |
| Kaleo, INC. | $482.46 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $429.11 | 2019-2025 | |
| Genentech USA, INC. | $427.44 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $410.59 | 2021-2025 | Orladeyo |
| Abbvie INC. | $368.08 | 2021-2025 | |
| Optinose US, INC. | $313.94 | 2019-2025 | |
| Pharming Healthcare, INC. | $279.13 | 2019-2025 | Ruconest |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $254.33 | 2019-2022 | |
| Blueprint Medicines Corporation | $212.15 | 2021-2024 | Ayvakit |
| Shire North American Group INC | $205.67 | 2019 | |
| Adma Biomanufacturing LLC | $189.62 | 2022-2024 | |
| Grifols USA, LLC | $172.86 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $171.80 | 2022-2025 | Actimmune, Tezspire |
| Teva Pharmaceuticals USA, INC. | $107.19 | 2019-2021 | |
| Incyte Corporation | $98.57 | 2022-2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $75.06 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $61.35 | 2020-2023 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $59.24 | 2025 | Neffy |
| Organon LLC | $58.35 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $55.63 | 2021-2023 | |
| Phadia US INC. | $55.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.50 | 2025 | Invega Trinza, Invega Sustenna |
| Leo Pharma INC. | $29.16 | 2022 | |
| Tersera Therapeutics LLC | $26.86 | 2023 | Quzyttir |
| Covis Pharma Gmbh | $22.88 | 2021 | |
| Horizon Therapeutics Plc | $20.92 | 2022 | |
| Hikma Pharmaceuticals USA | $17.96 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $17.28 | 2025 | Xhance |
| Galderma Laboratories, L.P. | $13.98 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.